New treatments for inflammatory rheumatic disease

Carlo Selmi, Elena Generali, Marco Massarotti, Gerolamo Bianchi, Carlo A. Sciré

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several biotechnological agents have been developed, most of them indicated in the treatment of rheumatoid arthritis, but also psoriatic arthritis. Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. Most novel treatments are being developed for arthritis with specific differences between rheumatoid and psoriatic arthritis, as well as for systemic lupus erythematosus, following the approval of belimumab. Finally, biologic therapies are effective also in gout, mainly targeting interleukin-1 to block the inflammasome. This review article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules.

Original languageEnglish (US)
Pages (from-to)277-288
Number of pages12
JournalImmunologic Research
Volume60
Issue number2-3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Rheumatic Diseases
Psoriatic Arthritis
Rheumatoid Arthritis
Gout
Systemic Lupus Erythematosus
Inflammasomes
Janus Kinases
Biological Therapy
Therapeutics
Interleukin-1
Autoimmune Diseases
Arthritis
Interleukin-6
B-Lymphocytes
Tumor Necrosis Factor-alpha
Inflammation
Etanercept
belimumab

Keywords

  • Biologics
  • Gout
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology

Cite this

Selmi, C., Generali, E., Massarotti, M., Bianchi, G., & Sciré, C. A. (2014). New treatments for inflammatory rheumatic disease. Immunologic Research, 60(2-3), 277-288. https://doi.org/10.1007/s12026-014-8565-5

New treatments for inflammatory rheumatic disease. / Selmi, Carlo; Generali, Elena; Massarotti, Marco; Bianchi, Gerolamo; Sciré, Carlo A.

In: Immunologic Research, Vol. 60, No. 2-3, 2014, p. 277-288.

Research output: Contribution to journalArticle

Selmi, C, Generali, E, Massarotti, M, Bianchi, G & Sciré, CA 2014, 'New treatments for inflammatory rheumatic disease', Immunologic Research, vol. 60, no. 2-3, pp. 277-288. https://doi.org/10.1007/s12026-014-8565-5
Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA. New treatments for inflammatory rheumatic disease. Immunologic Research. 2014;60(2-3):277-288. https://doi.org/10.1007/s12026-014-8565-5
Selmi, Carlo ; Generali, Elena ; Massarotti, Marco ; Bianchi, Gerolamo ; Sciré, Carlo A. / New treatments for inflammatory rheumatic disease. In: Immunologic Research. 2014 ; Vol. 60, No. 2-3. pp. 277-288.
@article{5c42868cc5d0469084a4a04103ca331e,
title = "New treatments for inflammatory rheumatic disease",
abstract = "As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several biotechnological agents have been developed, most of them indicated in the treatment of rheumatoid arthritis, but also psoriatic arthritis. Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. Most novel treatments are being developed for arthritis with specific differences between rheumatoid and psoriatic arthritis, as well as for systemic lupus erythematosus, following the approval of belimumab. Finally, biologic therapies are effective also in gout, mainly targeting interleukin-1 to block the inflammasome. This review article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules.",
keywords = "Biologics, Gout, Psoriatic arthritis, Rheumatoid arthritis, Systemic lupus erythematosus",
author = "Carlo Selmi and Elena Generali and Marco Massarotti and Gerolamo Bianchi and Scir{\'e}, {Carlo A.}",
year = "2014",
doi = "10.1007/s12026-014-8565-5",
language = "English (US)",
volume = "60",
pages = "277--288",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - New treatments for inflammatory rheumatic disease

AU - Selmi, Carlo

AU - Generali, Elena

AU - Massarotti, Marco

AU - Bianchi, Gerolamo

AU - Sciré, Carlo A.

PY - 2014

Y1 - 2014

N2 - As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several biotechnological agents have been developed, most of them indicated in the treatment of rheumatoid arthritis, but also psoriatic arthritis. Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. Most novel treatments are being developed for arthritis with specific differences between rheumatoid and psoriatic arthritis, as well as for systemic lupus erythematosus, following the approval of belimumab. Finally, biologic therapies are effective also in gout, mainly targeting interleukin-1 to block the inflammasome. This review article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules.

AB - As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several biotechnological agents have been developed, most of them indicated in the treatment of rheumatoid arthritis, but also psoriatic arthritis. Most currently available molecules target TNF-alfa with different strategies (i.e., etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), IL-6 (tocilizumab), CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the cascade of inflammation. Further, small molecules have been recently developed to target intracellular signaling, such as Janus Kinases for tofacitinib, the first FDA-approved small molecule for rheumatoid arthritis. Most novel treatments are being developed for arthritis with specific differences between rheumatoid and psoriatic arthritis, as well as for systemic lupus erythematosus, following the approval of belimumab. Finally, biologic therapies are effective also in gout, mainly targeting interleukin-1 to block the inflammasome. This review article describes the new and upcoming treatment options for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and gout to dissect what we should be aware of when discussing these new and promising molecules.

KW - Biologics

KW - Gout

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84922073620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922073620&partnerID=8YFLogxK

U2 - 10.1007/s12026-014-8565-5

DO - 10.1007/s12026-014-8565-5

M3 - Article

C2 - 25381481

AN - SCOPUS:84922073620

VL - 60

SP - 277

EP - 288

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 2-3

ER -